Mind Medicine MindMed (MNMD)
(Delayed Data from NSDQ)
$5.92 USD
+0.11 (1.81%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $5.93 +0.02 (0.25%) 5:28 PM ET
2-Buy of 5 2
D Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.92 USD
+0.11 (1.81%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $5.93 +0.02 (0.25%) 5:28 PM ET
2-Buy of 5 2
D Value C Growth C Momentum C VGM
Zacks News
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
by Zacks Equity Research
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
by Zacks Equity Research
MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag
by Zacks Equity Research
The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.
What Makes Mind Medicine (MindMed) Inc. (MNMD) a New Buy Stock
by Zacks Equity Research
Mind Medicine (MindMed) Inc. (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study
by Zacks Equity Research
MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expected in late 2023.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
by Andrew Rocco
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Mind Medicine MindMed (MNMD) is expected to provide an update on its pipeline candidates in its third-quarter earnings.
Mind Medicine MindMed Inc. (MNMD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Mind Medicine MindMed Inc. (MNMD) closed at $2.80, marking a -1.41% move from the previous day.
5 Top Stocks to Buy on New Analysts' Coverage
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Napco Security (NSSC), Proto Labs (PRLB), Clear Secure (YOU), AVEO and Mind Medicine (MNMD).
Wall Street Analysts Predict a 399% Upside in Mind Medicine MindMed Inc. (MNMD): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 399.3% upside potential for Mind Medicine MindMed Inc. (MNMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Earnings Season Could Be Great for Mind Medicine (MNMD)
by Zacks Equity Research
Mind Medicine (MNMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Do Options Traders Know Something About MindMed (MNMD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to MindMed (MNMD) stock based on the movements in the options market lately.